Drugs in MeSH Category Analgesics, Non-Narcotic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
West Ward	AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride	TABLET;ORAL	087647-001	Mar 5, 1982		DISCN	No	No
Sunshine	IBUPROFEN	ibuprofen	TABLET;ORAL	204062-003	Sep 10, 2018		DISCN	No	No
Osmotica Pharm Us	CARBAMAZEPINE	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	215664-003	Oct 22, 2024		DISCN	No	No
Aurobindo Pharma	ACETAMINOPHEN	acetaminophen	TABLET, EXTENDED RELEASE;ORAL	207229-001	Nov 9, 2016		OTC	No	No
Taro	CARBAMAZEPINE	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	201106-002	Jun 21, 2013		DISCN	No	No
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-003	Feb 16, 2018		DISCN	Yes	No	10,512,617

Market dynamics and patent landscape for drugs in NLM MeSH Class: Analgesics, Non-Narcotic

Last updated: April 22, 2026

Non-narcotic analgesics is a MeSH umbrella that largely maps to OTC and prescription pain therapies across NSAIDs (including COX-2 selective agents), acetaminophen, and other non-opioid analgesic classes (for example, adjuvants used in neuropathic pain). In market terms, the category is dominated by mature small molecules with extensive patent expiry, with recurring patent “islands” driven by line extensions, new formulations, and new-dose regimens. In patent terms, the landscape is shaped by (1) frequent generic entry, (2) formulation and use patents that support branded longevity, and (3) regulatory exclusivities that can delay full generic substitution even when composition-of-matter protection is weak or expired.

How big is the market and what drives unit demand in non-narcotic analgesics?

Market structure

Non-narcotic analgesics split into:

• OTC pain relievers (chiefly acetaminophen and OTC NSAIDs in many geographies), where brand differentiation is limited and pricing follows competitive generic dynamics.
• Prescription non-opioid analgesics, where branded share persists through targeted indications, dosing convenience, and payer/formulary positioning.

Demand drivers (what moves sales)

The category’s unit demand is most sensitive to:

• Incidence and treatment patterns for mild to moderate acute pain (headache, musculoskeletal pain, dysmenorrhea) and chronic pain conditions treated with non-opioids.
• Switching between OTC and prescription based on safety messaging, prescriber behavior, and payer criteria.
• Safety trade-offs across NSAID and acetaminophen pathways:
  • NSAIDs: gastrointestinal and cardiovascular risk management drives restriction and selective use.
  • Acetaminophen: liver safety drives dosing limits and combination-product controls.

Competitive and pricing dynamics

• Generic penetration is high across long-established molecules (examples: ibuprofen, naproxen, diclofenac, acetaminophen).
• Brand value concentrates in:
  • Renal- or GI-risk differentiated NSAID profiles (where supported by label and evidence),
  • Long-acting and topical formats (which can support non-interchangeable offerings),
  • Narrower indication approvals and post-marketing safety narratives.

Actionable implication: if a new entrant targets this MeSH class, the credible path to revenue is rarely “new molecule only.” It is usually a defensible differentiation layer: formulation, dosing convenience, patient selection, or a label expansion that creates formulary access.

Which patent types matter most for analgesics, non-narcotic?

Patent portfolios in this class usually use layered protection. For business evaluation, the highest-yield assets are the ones that block manufacturing and not just marketing.

1) Composition-of-matter (CoM)

• Many core NSAIDs and acetaminophen have long expired CoM terms.
• New CoM is rarer because most chemical space is consolidated, and incremental chemistry faces strong generic pressure.

2) Method-of-use and dosing regimen patents

• Common where a new indication or dosing regimen creates a label-linked barrier.
• In practice, generic entry can still occur if the generic can practice the FDA-approved label while avoiding the patented method (or by designing around claim scope).

3) Formulation and delivery patents

• Extended-release (ER) / controlled-release: supports distinct manufacturing claims and hard-to-interchange strengths.
• Topical and transdermal formats: can create separate claim sets tied to particle size, vehicle, permeability, and release kinetics.
• Combination products: claim sets often cover fixed-dose combinations, ratios, and abuse-deterrence-like release profiles (even when not opioid-based, some products apply similar release controls).

4) Polymorph and solid-state form patents

• Most relevant for APIs where polymorph control improves stability, manufacturability, or bioavailability.
• Industry practice uses solid-state patents to extend exclusivity even for known scaffolds.

5) Patent term adjustment and regulatory exclusivity

Even when CoM expires, regulatory exclusivities can sustain branded revenue:

• Orphan Drug Exclusivity (rare for common analgesics).
• Pediatric exclusivity (if requested and applicable).
• New drug application (NDA) and abbreviated approval pathways can trigger Hatch-Wins.
• Extended-release and new formulation approvals can create separate NDA exclusivities if the regulatory pathway qualifies.

Actionable implication: in this category, the “patent that blocks” is often a formulation or a method linked tightly to the branded label. When CoM is weak, the investor’s diligence focus shifts to claim scope, enforceability, and design-around feasibility.

How does generic entry typically happen in this MeSH class?

Generic entry in non-narcotic analgesics follows a repeatable pattern:

1. CoM expiry reduces the primary legal barrier.
2. Branded holders pivot to:
   • additional patents (use, formulation, solid state),
   • REMS-like safety framing (not necessarily patentable),
   • bundling into plan-covered tiers.
3. Generic manufacturers file for FDA approval with Paragraph IV certifications (when patents exist).
4. Litigation delays market entry but rarely prevents it permanently unless a claim is upheld or a formulation-specific claim remains enforceable.

The economic result is:

• fast price compression after entry for OTC-like products,
• longer branded tail for non-interchangeable formulations or narrow indication-driven reimbursements.

Actionable implication: value protection depends on whether the branded product is “substitutable.” If payers and pharmacy benefit managers treat the branded product as interchangeable with generics, patent value declines even with pending cases.

What is the patent landscape like by analgesic subtype?

NSAIDs (non-selective and COX-2 selective)

Landscape characteristics

• High historical CoM expiry across major agents.
• Ongoing patent activity concentrated in:
  • ER formulations and topicals,
  • dose regimens tied to label differentiation,
  • subpopulations (example: arthritis sub-indications).
• COX-2 selectivity has historically been a patent driver in past generations, but current competitive sets are mature.

Business lens

• CoM is usually not the value anchor in NSAIDs for new licensing deals.
• Formulation and line-extension portfolios matter more for near-term exclusivity leverage.

Acetaminophen

Landscape characteristics

• CoM expiry is common.
• Patent activity tends to center on:
  • combination products (ratios and release profiles),
  • rapid onset vs extended action formulations,
  • stability and manufacturing solid-state improvements,
  • use in specific settings (label-specific dosing; still often challenging to maintain against design-around).

Business lens

• High threat from generic substitution when the branded product is considered therapeutically equivalent.

Adjuvant analgesics used for pain (neuropathic and chronic pain)

This MeSH class can include non-opioid analgesics that target pain pathways outside classic NSAID/acetaminophen mechanisms (for example, anticonvulsant and antidepressant classes used for neuropathic pain). Patent landscapes here can be more active than in NSAIDs because:

• multiple mechanisms have ongoing CoM in more recent waves,
• new formulations or dosing titration schedules can remain patent-protected longer.

Business lens

• These markets show slower generic creep when the branded dosing schedule is distinct or the formulation is hard to copy.

What are the main risks for a new entrant pursuing patents in this class?

Key diligence risks:

• Claim validity risk: incremental chemistry and predictable formulation improvements can face obviousness challenges.
• Design-around risk: if a competitor can launch a generic that avoids the asserted use claim while remaining within the labeled indication, injunction value drops.
• Regulatory substitution risk: even with an active injunction, payer formularies can shift to alternative classes, limiting branded revenue exposure.
• Enforcement cost: frequent litigation with mature markets can make enforcement ROI unattractive without clear claim strength.

What is the most actionable way to map patents to commercial outcomes?

A practical mapping model for analgesics, non-narcotic:

1. Identify product’s “substitutability tier.”

   • Full generic substitution: CoM likely weak.
   • Partial substitution: formulation and delivery can create separation.
   • Minimal substitution: tied to specific dosing or unique mechanism with active CoM.

2. Score each patent by its blocking power.

   • Blocking power is strongest for manufacturing claims (formulation, solid-state, delivery).
   • Blocking power is weaker for broad use claims with easy design-around.

3. Overlay timeline to key regulatory events.

   • Patent expiry,
   • expected ANDA entry windows,
   • any exclusivity that can extend revenue despite patent weakness.

4. Stress-test claim scope vs generic development.

   • Can a generic replicate the branded release profile or solids?
   • Can a generic maintain therapeutic equivalence while avoiding the patented method?

What do these dynamics imply for investors and R&D teams?

If you are investing in branded non-narcotic analgesics

• Prioritize assets with:
  • formulation differentiation that limits substitution,
  • claim sets that target manufacturing or hard-to-replicate delivery,
  • strong label dependency (fewer off-label workarounds).
• Treat CoM-heavy but mature products as lower-risk for litigation outcomes but limited for long-duration upside.

If you are building an R&D pipeline

• Target differentiation that creates enforceable, non-obvious, and reproducible protection:
  • delivery system claims,
  • solid-state control,
  • dosing regimens that remain in-label and commercially enforced.
• Avoid relying solely on incremental chemistry where generic design-around is likely.

If you are licensing or acquiring portfolios

• The diligence focus should be:
  • remaining term by jurisdiction,
  • strength of asserted claims in litigation history,
  • freedom-to-operate around formulation and use,
  • ability for generics to meet therapeutic equivalence requirements without touching claim elements.

What key external references define the MeSH scope?

The NLM MeSH hierarchy:

• Analgesics, Non-Narcotic sits within the broader analgesics classification used for biomedical indexing and literature retrieval.
• The MeSH term is a retrieval classification; it does not define a single regulatory product category. As a result, the patent landscape is a composite of multiple regulatory and pharmacologic buckets mapped into the MeSH label.

Key Takeaways

• Non-narcotic analgesics are dominated by mature molecules with widespread generic availability, so patent value usually comes from formulations, dosing regimens, and line extensions rather than core CoM.
• NSAIDs and acetaminophen face intense substitution pressure; commercially meaningful patents tend to be those that reduce therapeutic interchangeability (ER, topical, hard-to-replicate solids).
• Portfolios should be evaluated on blocking power (manufacturing claims outperform use-only claims) and on timeline alignment with ANDA entry and regulatory exclusivity.
• The MeSH category is a search and indexing umbrella, so patent mapping must be done at the level of pharmacologic subtype and specific branded product rather than the MeSH term alone.

FAQs

1. Is “Analgesics, Non-Narcotic” a single patent class?
   No. It is a MeSH indexing category that aggregates multiple pharmacologic families, each with distinct patent and regulatory realities.

2. What patent types extend brand profitability the most in this category?
   Formulation and delivery patents (ER, topical, solid-state forms) and label-linked dosing patents, when they reduce substitutability and are enforceable against design-around.

3. Why do composition-of-matter patents often matter less here?
   Many core non-narcotic analgesics have long since reached CoM expiry, leaving line extensions and formulation barriers as the main sources of incremental exclusivity.

4. What is the main threat to branded non-opioid analgesics after patent expiry?
   Fast generic substitution for therapeutically equivalent formulations, driven by bioequivalence standards and payer interchangeability policies.

5. How should an investor model upside for new IP in non-narcotic analgesics?
   Use a claim-blocking and substitution framework: score patents by manufacturability barriers, enforceability, and how closely the branded product is tied to an in-label use that generics cannot easily practice.

References

[1] National Library of Medicine. MeSH Browser. “Analgesics, Non-Narcotic.” https://meshb.nlm.nih.gov/
[2] FDA. Drug Approval Reports and Approval Pathways (ANDAs, NDAs, and exclusivity concepts). https://www.fda.gov/drugs/
[3] FDA. Abbreviated New Drug Application (ANDA) submissions and generic approval framework. https://www.fda.gov/drugs/
[4] 35 U.S.C. § 156 (Patent term adjustments for FDA-regulated products) and related patent term provisions. https://uscode.house.gov/